Milutinovic, S.; Jancic, P.; Jokic, V.; Petrovic, M.; Dumic, I.; Rodriguez, A.M.; Tanasijevic, N.; Begosh-Mayne, D.; Stanojevic, D.; Escarcega, R.O.;
et al. Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System. Pharmaceuticals 2024, 17, 1372.
https://doi.org/10.3390/ph17101372
AMA Style
Milutinovic S, Jancic P, Jokic V, Petrovic M, Dumic I, Rodriguez AM, Tanasijevic N, Begosh-Mayne D, Stanojevic D, Escarcega RO,
et al. Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System. Pharmaceuticals. 2024; 17(10):1372.
https://doi.org/10.3390/ph17101372
Chicago/Turabian Style
Milutinovic, Stefan, Predrag Jancic, Vera Jokic, Marija Petrovic, Igor Dumic, Ambar Morales Rodriguez, Nikola Tanasijevic, Dustin Begosh-Mayne, Dragana Stanojevic, Ricardo O. Escarcega,
and et al. 2024. "Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System" Pharmaceuticals 17, no. 10: 1372.
https://doi.org/10.3390/ph17101372
APA Style
Milutinovic, S., Jancic, P., Jokic, V., Petrovic, M., Dumic, I., Rodriguez, A. M., Tanasijevic, N., Begosh-Mayne, D., Stanojevic, D., Escarcega, R. O., Lopez-Mattei, J., & Cao, X.
(2024). Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System. Pharmaceuticals, 17(10), 1372.
https://doi.org/10.3390/ph17101372
